Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines

Joint Bone Spine. 2014 Oct;81(5):461-2. doi: 10.1016/j.jbspin.2014.02.012. Epub 2014 Apr 2.

Authors

Christopher Banse¹, Patrice Fardellone², Julien Paccou²

Affiliations

¹ Department of Rheumatology, CHU d'Amiens, University of Picardie Jules Verne, 80054 Amiens, France; Department of Rheumatology, CHU de Rouen, University of Rouen, 76031 Rouen, France. Electronic address: [email protected].
² Department of Rheumatology, CHU d'Amiens, University of Picardie Jules Verne, 80054 Amiens, France; Unité Inserm U1088, Université de Picardie-Jules-Verne, 80054 Amiens, France.

PMID: 24703403
DOI: 10.1016/j.jbspin.2014.02.012

No abstract available

Keywords: Allopurinol; Asymptomatic hyperuricaemia; Comorbidities; Febuxostat; Gout; Urate-lowering therapy.

Publication types

Letter

MeSH terms

Aged
Allopurinol / therapeutic use
Febuxostat
Female
Gout / blood
Gout / drug therapy*
Gout Suppressants / therapeutic use*
Guideline Adherence
Hospitalization
Humans
Hyperuricemia / drug therapy*
Male
Prevalence
Thiazoles / therapeutic use
Xanthine Oxidase / antagonists & inhibitors*

Substances

Gout Suppressants
Thiazoles
Febuxostat
Allopurinol
Xanthine Oxidase